文献速递胸部肿瘤

度伐利尤单抗巩固治疗在EGFR/HER2突变不可切除III期NSCLC中的作用

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-02-01

该回顾性分析纳入2018年1月至2020年3月接受根治性放化疗后度伐利尤单抗巩固治疗的不可切除III期NSCLC患者36例,其中14例存在ERBB家族突变(11例EGFR、3例ERBB2)。ERBB2/EGFR突变队列较野生型队列无病生存期显著缩短(7.5个月 vs 未达到,p=0.04)。提示度伐利尤单抗巩固治疗在ERBB2/EGFR突变患者中疗效可能较差。

要点

  • ERBB2/EGFR突变患者度伐利尤单抗巩固治疗后DFS显著缩短(7.5个月 vs 未达到,p=0.04)。
  • ERBB2/EGFR突变队列更可能为非吸烟者,其余基线特征与野生型组相似。
  • 结果提示需前瞻性研究验证并探索ERBB2/EGFR突变III期NSCLC的最佳治疗。

核心结论

  • 度伐利尤单抗巩固治疗在ERBB2/EGFR突变不可切除III期NSCLC患者中疗效可能较差。

研究设计与样本

  • 回顾性分析纳入2018年1月至2020年3月接受根治性放化疗后度伐利尤单抗巩固治疗的不可切除III期NSCLC患者36例。

主要发现

  • 14例患者存在ERBB家族突变,包括11例EGFR和3例ERBB2。
  • ERBB2/EGFR突变队列较野生型队列更可能为非吸烟者,两组在年龄、性别、PD-L1表达和既往化疗方案类型方面相似。
  • ERBB2/EGFR突变队列较EGFR或ERBB2野生型队列无病生存期显著缩短(7.5个月 vs 未达到,p=0.04)。

临床怎么用

  • 对不可切除III期NSCLC患者,ERBB2/EGFR突变状态可能有助于预判度伐利尤单抗巩固治疗获益。
  • ERBB2/EGFR突变患者接受度伐利尤单抗巩固治疗需密切随访,并考虑探索替代或优化治疗策略。

局限性

  • 回顾性分析,样本量小(36例),ERBB2/EGFR突变亚组仅14例。
  • 需前瞻性研究验证上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the recent advance of consolidation durvalumab in the treatment of unresectable stage III NSCLC, not every patient benefits from durvalumab and the predictive markers of response have been difficult to identify. METHODS: We performed a retrospective analysis of patients with unresectable stage III NSCLC treated with consolidation durvalumab after definitive chemoradiation from January 2018 to March 2020. RESULTS: A total of 36 patients with unresectable stage III NSCLC were treated with consolidation durvalumab. Of these patients, 14 had tumor mutations in the ERBB family including 11 EGFR and 3 ERBB2. The ERBB2/EGFR tumor mutation cohort was more likely to be nonsmokers; otherwise, the two groups were similar in age, sex, programmed death-ligand 1 expression, and type of previous chemotherapy regimen. Patients in the ERBB2/EGFR cohort had a significantly shorter disease-free survival compared with the EGFR or ERBB2 wild-type cohort (7.5 mo versus not reached, p = 0.04). CONCLUSIONS: Consolidation durvalumab seems to be less efficacious in patients with ERBB2/EGFR-mutant tumors. Future work should seek to evaluate this in the prospective setting and provide insight into the optimal treatment of ERBB2/EGFR-mutant stage III NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hellyer JA, Aredo JV, Das M, et al. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. J Thorac Oncol. 2021. PMID: 33539970. doi:10.1016/j.jtho.2020.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。